FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation
Congressional investigators sorted through more than 500,000 pages of documents from the Food and Drug…
Category: drug pricing
Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say
The latest Alzheimer’s disease treatment from Eisai and Biogen needs to be cheaper than $20,000…
STAT+: AbbVie exits major pharmaceutical industry lobbying groups
WASHINGTON — The maker of one of the world’s most profitable medicines is exiting the…
STAT+: Amid criticism over unaffordable insulin, Lilly strikes a manufacturing deal to supply Africa
In a bid to widen access to insulin in primarily low-income nations in Africa, Eli…
Opinion: Fixing price instability can improve access to affordable prescription drugs
The high cost of prescription drugs is a very real problem in the United States….
STAT+: Lawmakers tell Pfizer CEO to ‘back off’ on planned price hike for Covid-19 vaccine
A pair of U.S. lawmakers wrote Pfizer chief executive officer Albert Bourla that he should…
STAT+: Why a tone-deaf Regeneron executive deserved to be booed over Alzheimer’s drug pricing
File this under “What was he thinking?” The otherwise staid Milken Institute summit on health…
STAT+: Mark Cuban teams with a business coalition in bid to lower drug costs for employers
In his latest bid to expand access to lower-cost medicines, Mark Cuban’s Cost Plus Drug…
STAT+: The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $805 million in 2021
During 2021, drugmakers substantially raised prices on seven widely used medicines without any new clinical…
STAT+: “This is not a cure”: Consensus begins to emerge on new Alzheimer’s drug
NEW YORK — A consensus may be emerging about how to prescribe the new Alzheimer’s…
STAT+: A year after petition, NIH reviews request to lower cancer drug’s cost by sidestepping patents
One year after being asked to widen access to a pricey cancer treatment by using…
STAT+: Afraid of pharma pushback, a health data broker puts up a barrier to drug pricing information
At a time when many Americans are clamoring for more transparency into prescription drug pricing,…
STAT+: PhRMA, once invincible in Washington, has lost its edge
WASHINGTON — PhRMA has a reputation in Washington for might, for money, for scorched-earth tactics,…
STAT+: ‘Skinny labels’ on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period
A hotly contested provision of a federal law designed to speed copycat drugs to market…
In a Republican-led House, anti-science probes top the agenda
WASHINGTON — The Covid-19 investigations are coming. When Republicans take control of the House of Representatives…
STAT+: Lilly CEO concedes Twitter flap over insulin costs shows there’s ‘more work to do’
After a tweet from a fake corporate account last week claimed Eli Lilly would give…
STAT+: Spain’s antitrust regulator fines drugmaker for ‘excessive’ pricing of a rare disease drug
Antitrust regulators in Spain have fined a drugmaker $10.6 million for years of “excessive” price…
STAT+: For its first two medicines, EQRx abandons its bold strategy to lower drug prices
Changing the way cancer drugs are priced in the U.S. is apparently even harder than…
Health and science are on the ballot this election. Here’s what we’re watching
WASHINGTON — The midterm elections this year are centered on weighty topics: the economy looms…
STAT+: Drugmaker raises the price of an old chemo medicine tenfold amid persistent shortages
Amid sporadic shortages of a drug that is essential in preparing patients for lifesaving, cancer-fighting…
Opinion: After 30 years of 340B, it’s time for data and an honest conversation
The 340B Drug Discount Program turns 30 on Nov. 4. This once-obscure drug access program…
STAT+: Merck fined $39 million by Spain’s antitrust regulator for ‘serious’ violation
The antitrust regulator in Spain has fined Merck approximately $39 million for preventing a competitor…
STAT+: How one pharma insider sees the drug pricing reform law: the impact will ‘vary by product and by company’
After years of stops and starts, a law was finally passed in Congress this summer…
Opinion: How states can act to limit drug price increases, saving employers and workers billions
The Inflation Reduction Act of 2022 mandates that Medicare-covered drug sales will be protected from…
.jpg)
STAT+: Drugmakers will be penalized if they hike prices on patients in private insurance market
WASHINGTON — Democrats’ drug pricing law will still penalize drugmakers if they hike prices on…
STAT+: Medicare tasks a senior adviser with staffing its new drug pricing division
WASHINGTON — Medicare has tasked a senior adviser at the agency with assembling a small…
STAT+: Medicare lays out the bureaucracy it will need to negotiate drug prices
WASHINGTON — New documents obtained by STAT outline how Medicare is planning to build out…
STAT+: Democrats concede to clean user fee agreement to fund FDA
WASHINGTON — Democrats have conceded to Republican demands and agreed to fund the Food and…
STAT+: White House pitches drug pricing reforms as a way to extend cancer patients’ lives
WASHINGTON — The White House is pitching an added benefit to Democrats’ recent drug pricing…
STAT+: Inflation caused another big drop in net drug prices, analysis finds
Amid ongoing debate over the cost of prescription medicines, a new analysis finds that brand-name…
Opinion: Market share isn’t the only metric for biosimilars’ success
Market share is often held up as the most relevant metric for the success of…
STAT+: Patients for Affordable Drugs taps new leader
WASHINGTON — One of Washington’s most prominent drug pricing patient groups is tapping an advocate who…
STAT+: Brazil dismisses antitrust complaint against Gilead over pricing for a hepatitis C drug
In a victory for Gilead Sciences, Brazilian antitrust authorities dismissed a complaint filed by several…
STAT+: Swiss authorities raid Novartis offices seeking info on patents used to block rivals
The Swiss Competition Commission has begun an investigation into Novartis over the possible unlawful use…
STAT+: J&J wins a partial appeal against the U.K.’s cost-effectiveness watchdog over ‘unfair’ review
In an unusual turn of events, an appeals panel ruled that the U.K.’s cost effectiveness…
Opinion: Launch prices: tackling the next drug pricing challenge
The passage of the Inflation Reduction Act brings a new era to drug pricing in…
STAT+: Pharma donations to patient charities may violate the ‘spirit’ of anti-kickback laws
There is a federal law that prohibits drug companies from directly covering out-of-pocket spending by…
STAT+: Centene agrees to pay $33 million to resolve another state probe into its pharmacy benefits business
Centene, one of the largest health insurers in the U.S., agreed to pay $33 million…
Opinion: The Inflation Reduction Act: One step closer to pharmacoequity?
President Biden’s signing of the Inflation Reduction Act on Tuesday marked a health care law…
STAT+: Medicare may eventually negotiate some drug prices, but Colorado still wants to import medicines from Canada
The Biden administration may have signed a law designed to lower prescription drug prices, but…
STAT+: Pharma’s likely to sue over Medicare negotiation. Here are the arguments they might use
WASHINGTON — Democrats finally achieved a win over the pharmaceutical industry this month when they…
STAT+: Cepheid faces fresh criticism over the pricing of its TB diagnostics
A controversy has broken out over a diagnostic for tuberculosis that, until recently, had been…
STAT+: Unpacking the drug pricing policies that Congress just approved
WASHINGTON — Medicare coverage for prescription drugs will look very different when President Biden signs…
STAT+: Sales from controversial drug discount program rose to $44 billion last year
Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $44…
STAT+: Cancer patient who devoted six years to drug pricing reform isn’t done yet
BETHESDA, Md. — After six years of relentless advocacy work, David Mitchell was finally on…
In a momentous vote for Pelosi, House sends drug pricing reforms to President Biden’s desk
WASHINGTON — Fifteen years later, House Speaker Nancy Pelosi is fulfilling one of her first campaign…
STAT+: Wyden wants details on Amgen’s U.S. taxes as part of expanding probe into pharma practices
The head of the U.S. Senate Finance Committee is seeking details from Amgen about the…
Listen: Big egos in Big Science, the return of Merger Monday, & the fallout over drug pricing
Are biotech’s fortunes finally changing? Is Big Science impeding actual science? And what will Medicare…
Here’s who Democrats’ drug pricing bill will actually help
WASHINGTON — Millions of patients in the Medicare program could eventually see lower prescription drug costs…
STAT+: For the second time, Pfizer tries a drug warranty in response to concerns over high costs
For only the second time, Pfizer is offering a warranty for a medicine that will…